Title: Time between Symptom Onset and Assessment in Age-Related Macular Degeneration with Subfoveal Choroidal Neovascularization
Abstract: <i>Background:</i> Therapy delay in neovascular age-related macular degeneration (NV-AMD) is associated with risk of visual deterioration. <i>Methods:</i> Retrospective cross section analysis including patients with NV-AMD who received fluorescein angiography (FA). The time elapsed from symptom onset to assessment was analysed in relation to different factors. Inclusion criteria were: age >50 years, symptom onset within 6 months before assessment, no previous AMD therapy, indication for vascular endothelial growth factor inhibitor treatment. <i>Results:</i> Mean duration of symptoms was 2.272 ± 1.683 months (n = 220); percentiles 25, 50, 75 and 90 corresponded to 1, 2, 3 and 5.383 months. A significant increase (p = 0.033) in mean symptom duration was found between age groups 65–74, 75–84 and over 84 years. Privately insured persons (assessment 1.242 ± 1.060 months after symptom onset; n = 14) received FA 1.083 months earlier (p = 0.0089) than patients with a statutory health insurance (assessment 2.325 ± 1.661 months after symptom onset; n = 194). <i>Conclusion:</i> In order to avoid progressive visual deterioration in patients with NV-AMD earlier assessment of these individuals should be aimed for.
Publication Year: 2009
Publication Date: 2009-09-16
Language: en
Type: article
Indexed In: ['crossref', 'pubmed']
Access and Citation
Cited By Count: 13
AI Researcher Chatbot
Get quick answers to your questions about the article from our AI researcher chatbot